KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) Research & Development (2016 - 2025)

Historic Research & Development for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $71.4 million.

  • Cme's Research & Development rose 720.72% to $71.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.7 million, marking a year-over-year increase of 1009.65%. This contributed to the annual value of $255.8 million for FY2024, which is 1696.39% up from last year.
  • According to the latest figures from Q3 2025, Cme's Research & Development is $71.4 million, which was up 720.72% from $70.9 million recorded in Q2 2025.
  • In the past 5 years, Cme's Research & Development ranged from a high of $71.4 million in Q3 2025 and a low of $45.8 million during Q4 2021
  • In the last 5 years, Cme's Research & Development had a median value of $53.3 million in 2023 and averaged $56.0 million.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 1455.22% in 2021, then surged by 2026.27% in 2024.
  • Over the past 5 years, Cme's Research & Development (Quarter) stood at $45.8 million in 2021, then grew by 9.17% to $50.0 million in 2022, then grew by 17.0% to $58.5 million in 2023, then rose by 12.31% to $65.7 million in 2024, then increased by 8.68% to $71.4 million in 2025.
  • Its Research & Development was $71.4 million in Q3 2025, compared to $70.9 million in Q2 2025 and $65.7 million in Q1 2025.